Clinical trials: Cetuximab
Colorectal Cancer
Cetuximab Monotherapy Maintenance Treatment in mCRC
Investigating the efficacy of Cetuximab Monotherapy versus Continuation after induction treatment with chemotherapy + Cetuximab in inoperable or irresectable and non-progressive metastatic colorectal cancer after first line…
- Trial name
- NCT02978313
- Testing
- Cetuximab, mFOLFOX6, FOLFIRI
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Ruijin Hospital
Head and Neck Cancer, Chronic Periodontitis
Estimation of (suPAR) in Chronic Periodontitis With Post-radiotherapy on HNCs Patients
This study aims to improve a soluble urokinase plasminogen activator receptor suPAR is a reliable biomarker of chronic periodontitis and may be replaced in patients with head and neck cancer post-radiotherapy (HNC post-RT).
- Conditions
- Head and Neck Cancer, Chronic Periodontitis, Radiotherapy Side Effect
- Trial name
- HNCs (NCT06529588)
- Testing
- Radiation
- Where
- Iraq
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Al-Maarif University College
Metastatic Solid Tumors, Advanced Non-squamous Non-small-cell Lung Cancer
A First-in-human Study of BGB-53038, a Pan-KRAS Inhibitor, Alone or in Combinations in Participants With Advanced or Metastatic Solid Tumors With KRAS Mutations or Amplification
This is a first-in-human (FIH), open-label, multicenter, dose escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of BGB-53038 as…
- Conditions
- Metastatic Solid Tumors, Advanced Non-squamous Non-small-cell Lung Cancer, Advanced Colorectal Cancer, Advanced Pancreatic Ductal Adenocarcinoma
- Trial name
- NCT06585488
- Testing
- BGB-53038, Tislelizumab, Cetuximab
- Where
- 17 sites in United States, Australia and 3 more
- Volunteers
- 47 people, healthy volunteers welcome
- Sponsor
- BeOne Medicines
Colon Cancer, Colo-rectal Cancer
Targeted Polymeric Nanoparticles Loaded With Cetuximab and Decorated With Somatostatin Analogue to Colon Cancer
Due to the great toxicity of chemotherapeutic drugs to both the healthy and cancerous area, the efficient targeting could be of great benefit for a patient with advanced or metastatic tumors.
- Trial name
- NCT03774680
- Testing
- Cetuximab nanoparticles, Oral approved anticancer drug
- Where
- 4 sites in Egypt, Saudi Arabia
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Ahmed A. H. Abdellatif
Cancer, mCRC
Phase I PK Comparison of HLX05 vs. Erbitux® in Healthy Chinese Males: Safety, Immunogenicity, and Pharmacokinetics
This is a randomized, single intravenous dose, parallel study to compare the PK characteristics, safety, tolerability, and immunogenicity of HLX05 vs. Erbitux® (US-, EU-, and CN-sourced) in healthy adult male Chinese subjects.
- Trial name
- NCT06980454
- Testing
- HLX05, EU-Erbitux®, US-Erbitux®
- Where
- 2 sites in China
- Volunteers
- 322 people, healthy volunteers welcome
- Sponsor
- Shanghai Henlius Biotech
Cancer, Neoplasm
Study of SAR444881 Administered Alone and in Combination With Other Therapeutics in Participants With Advanced Solid Tumors
The study enrolled advanced cancer participants with unresectable or metastatic disease who were refractory to or were not candidates for standard approved therapy.
- Trial name
- NCT04717375
- Testing
- SAR444881, Pembrolizumab, Cetuximab
- Where
- 18 sites in United States, Canada and 2 more
- Volunteers
- 125 people, healthy volunteers welcome
- Sponsor
- Sanofi
Melanoma, Breast Cancer
Quantifying Systemic Immunosuppression to Personalize Cancer Therapy
The Serpentine (Stratify cancER PatiENTs by ImmuNosupprEssion) project, represents the most consistent effort so far attempted to translate MDSC into clinical practise by producing an off-the-shelf compliant assay for quantifying…
- Conditions
- Melanoma, Breast Cancer, Renal Cell Carcinoma, Urinary Bladder Cancer
- Trial name
- Serpentine (NCT05621837)
- Testing
- MDSC quantification
- Where
- Italy
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Metastatic Colorectal Cancer
Re-challenge of Anti-EGFR for Patients With RAS/BRAF Wild-type Metastatic CRC
The aim of the trial is to study the efficacy and safety of Cetuximab re-challenge for Chinese Patients with RAS/BRAF wild-type Metastatic Colorectal Cancer.
- Trial name
- NCT04224415
- Testing
- C225+CPT-11
- Where
- China
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- Yuhong Li
Oropharyngeal Carcinoma
Anti-EGFR Therapy With IMRT Concurrent Chemoradiotherapy in Locally Advanced OPC Resistant to Induction Chemotherapy
This study is a prospective phase II trial which is designed to evaluate the efficacy and safety of IMRT combined with concurrent chemotherapy and anti-EGFR monoclonal antibody in locally advanced oropharyngeal carcinoma (OPC)…
- Trial name
- NCT04508829
- Testing
- Anti-EGFR monoclonal antibody
- Where
- China
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- Fudan University
Glioblastoma Multiforme, Anaplastic Astrocytoma
Treatment of Relapsed/Refractory Intracranial Glioma in Patients Under 22 Years of Age
This study assesses the safety and efficacy of repeat monthly dosing of super-selective intra-arterial cerebral infusion (SIACI) of cetuximab and bevacizumab in patients < 22 years of age.
- Conditions
- Glioblastoma Multiforme, Anaplastic Astrocytoma, Fibrillary Astrocytomas, Oligodendroglioma
- Trial name
- NCT05956821
- Testing
- SIACI of cetuximab and bevacizumab
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- University of Miami
Nasopharyngeal Carcinoma
Study of Chemoradiotherapy Combined With Cetuximab in Nasopharyngeal Carcinoma
This is an open, multicenter phase Ⅱ clinical trial. The purpose of this study is to evaluate acute toxicity and efficacy of cetuximab (C225) combined with IMRT + neoadjuvant chemotherapy in advanced T stage of nasopharyngeal…
- Trial name
- REPLACE (NCT01271439)
- Testing
- Cetuximab
- Where
- China
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Sun Yat-sen University
Nasopharyngeal Carcinoma
Anti-EGFR Therapy Plus IMRT Concurrent Chemoradiotherapy in Locally Advanced NPC Resistant to Induction Chemotherapy
This study is a prospective phase II trial which is designed to evaluate the efficacy and safety of IMRT combined with concurrent chemotherapy and anti-EGFR monoclonal antibody in locally advanced nasopharyngeal carcinoma with…
- Trial name
- NCT04508816
- Testing
- cetuximab (CTX) or nimotuzumab (NTZ)
- Where
- China
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Fudan University
Healthy Volunteers
Clinical Trial to Evaluate Pharmacokinetics,Safety and Immunogenicity of Single Injection of CDP1 to Healthy Volunteers Compared to Erbitux
Background Colorectal cancer (CRC) is one of the most common human malignant tumors. The incidence and mortality of colorectal cancer in our country are on the rise.
- Trial name
- NCT03881787
- Testing
- anti-EGFR monoclonal antibody, Cetuximab injection
- Where
- 2 sites in China
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- Dragonboat Biopharmaceutical Company Limited
EGFR Overexpression
A Randomized, Single Intravenous Dose, Parallel Phase I Clinical Study to Compare the Pharmacokinetic Characteristics, Safety, and Immunogenicity of HLX05 Vs. Erbitux® (Cetuximab) in Healthy Adult Male Chinese Subjects
This is a randomized, single intravenous dose, parallel study to compare the PK characteristics, safety, tolerability, and immunogenicity of HLX05 vs. Erbitux® (US-, EU-, and CN-sourced) in healthy adult male Chinese subjects.
- Trial name
- NCT06309043
- Testing
- recombinant anti-EGFR human/murine chimeric monoclonal antibody injection
- Where
- China
- Volunteers
- 268 people, healthy volunteers welcome
- Sponsor
- Shanghai Henlius Biotech
Neoplasms
A Study of Irinotecan With Dabrafenib Plus Trametinib and Anti-EGFR in the Second Line of Therapy in People With Metastatic Colorectal Cancer
The purpose of this study is to evaluate the efficacy and toxicity of irinotecan with dabrafenib, cetuximab/panitumumab in the second line of treatment for the potential treatment of colorectal cancer that: has a metastatic…
- Trial name
- NCT06967155
- Testing
- • Drug: Dabrafenib • Drug: Trametinib • Drug: Cetuximab • Drug: Рanitumumab • Drug: Oxaliplatin • Drug: Irinotecan • Drug: Leucovorin • Drug: 5-FU
- Where
- Russia
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- Blokhin's Russian Cancer Research Center
Cetuximab, Bioequivalence
A Randomized, Double-Blind, Positive-Controlled, Parallel Pharmacokinetic Phase I Clinical Study of Cetuximab Injection Versus Erbitux in Healthy Male Subjects
A Randomized, Double-Blind, Positive-Controlled, Parallel Pharmacokinetic Phase I Clinical Study of Cetuximab Injection versus Erbitux in Healthy Male Subjects
- Conditions
- Cetuximab, Bioequivalence, Healthy Volunteers, Pharmacokinetics
- Trial name
- BT-HC034S-101 (NCT07813468)
- Testing
- HC034S, Erbitux (Cetuximab)
- Where
- China
- Volunteers
- 92 people, healthy volunteers welcome
- Sponsor
- HC Biopharma Inc.
Head and Neck Cancer, Chronic Periodontitis
suPAR is a Potential Biomarker of in Chronic Periodontitis Through the Impact of Post-radiotherapy on HNCs Patients
This study aims to improve a soluble urokinase plasminogen activator receptor suPAR is a reliable biomarker of chronic periodontitis and may be replaced in patients with head and neck cancer post-radiotherapy (HNC post-RT).
- Conditions
- Head and Neck Cancer, Chronic Periodontitis, Radiotherapy; Complications
- Trial name
- HNCs (NCT06481059)
- Testing
- Head and Neck cancer post-radiotherapy
- Where
- Iraq
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Al-Maarif University College
Objective Responsive Rate (ORR)
Dynamic Changes in Circulating Tumour Cells Protein Expression
This multicenter study, randomized, controlled of blood-based biomarker-driven targhet therapy. Patients were selectedm( at Hospital San Giovanni and Celio in Rome) according to CTCs results ( CTCs-guided managment performed at…
- Trial name
- Liquid-DRER2 (NCT06314997)
- Testing
- panitumumab (EGFR inhibitors)
- Where
- Italy
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Matteo's Friends
Wild-type KRAS,NRAS and BRAF V600E Metastatic Colorectal Cancer
Continuing Cetuximab Plus Chemotherapy After First Progression in Wild-type KRAS, NRAS and BRAF V600E Metastatic Colorectal Cancer
The aim of this study was to evaluate the efficacy and safety of continuing cetuximab combined with chemotherapy after first-line progression in wild-type KRAS,NRAS and BRAF colorectal cancer.
- Trial name
- NCT04718038
- Testing
- Cetuximab combind mFOLFOX6/FOLFIRI
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Henan Cancer Hospital